MICROPROBE AND OLYMPUS TO DEVELOP DNA PROBE-BASED DIAGNOSTIC SYSTEM
MICROPROBE AND OLYMPUS TO DEVELOP DNA
PROBE-BASED DIAGNOSTIC SYSTEM
GARDEN GROVE, Calif., Nov. 13 /PRNewswire/ -- MicroProbe Corp., based here, today announced that it has signed an agreement with Olympus Optical Co. Ltd. to jointly develop a diagnostic system based on MicroProbe's DNA probe technology.
Under the agreement, both companies will contribute proprietary technology toward the development of an automated diagnostic system for the rapid identification of certain disease pathogens. Financial details were not disclosed.
DNA probes are comprised of synthetic DNA subunits called oligonucleotides that are designed to bind to a single strand of target DNA unique to a specific organism. DNA probes are ideal diagnostic reagents because of their high hybridization specificity, low cost, precisely known sequence and chemical structure.
Based in Tokyo, Olympus Optical Co., Ltd. was founded in 1919 and maintains more than 20 subsidiaries and representative offices around the world. It encompasses business lines in a wide variety of products based on optical as well as electronic technology. Olympus commands a lead position in many areas of biomedical instrumentation including endoscopes, microscopes and clinical chemistry analyzers.
Founded in 1985, MicroProbe Corp. is a biomedical company focused on delivering DNA probe technologies for practical use in medicine. The privately held firm is commercializing synthetic DNA probes for the rapid identification of pathogens and the treatment of certain infectious diseases and cancers. The company operates three divisions -- a diagnostics and a therapeutics division located together in Bothell, Wash., and an OEM systems division operating as Source Scientific Systems in Garden Grove.
/CONTACT: John L. Bishop of MicroProbe, 714-894-7184/ CO: MicroProbe; Olympus Optical Co. ST: California IN: MTC SU: PDT JL -- SJ004 -- 4000 11/13/91 13:42 EST